newsfilter
← Latest News
Business Wire·

Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Study Met Primary Endpoint VAS Feeling High (p < 0.0001) Statistically Significant and Sustained Reductions in Key THC-Related CNS Symptoms Conference Call 8:30am Eastern Time Today Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-